Limits to international estimates of stroke costs.
Limits to international estimates of stroke costs.
复制标题
中风费用国际估算的限制。
DOI：
10.1161/strokeaha.109.564864
复制
发表时间：
2010
期刊：
影响因子：
8.3
通讯作者：
D. C. Low
中科院分区：
文献类型：
--
作者：
R. Low;A. Qureshi;D. C. Low
请参阅相关文章，第319-324页。
Lundstrom等人发现，与护理无痉挛的中风患者相比，护理有痉挛的中风患者的成本显著增加。1这是对我们理解中风及其成本的一个重要贡献。如果读者试图将Lundstrom等人的发现推广到其他国家，我们会看到他们的文章中没有明确的两个重要限制：痉挛的治疗和使用购买力平价(PPP)来估计其他国家的成本。
首先，他们研究中的痉挛患者没有接受痉挛的药物治疗。他们的患者没有接受肉毒杆菌毒素(肉毒杆菌毒素)治疗，甚至没有接受丹曲林、巴氯芬或苯二氮卓类药物治疗。如果痉挛得到了治疗，成本可能会更低。
其次，伦德斯特龙计划将成本转嫁给…以外的国家
See related article, pages 319–324.
Lundstrom et al show a marked increase in cost of caring for patients with stroke with spasticity compared with the cost of caring for patients with stroke without spasticity.1 This is an important contribution to our understanding of stroke and its costs. If a reader attempts to generalize Lundstrom et al’s findings to other countries, we see 2 important limitations that are not clear in their article: treatment of spasticity and using Purchasing Power Parities (PPPs) to estimate costs in other countries.
First, the spastic patients in their study were not treated pharmacologically for spasticity. Their patients were not treated with botulism toxin (Botox) or even dantrolene, baclofen, or benzodiazepines. Had the spasticity been treated, the costs might have been lower.
Second, Lundstrom projects the costs to countries outside of …